MediPoint:主動脈覆膜支架 - 歐盟市場分析與預測
MediPoint: Aortic Stent Grafts - EU Analysis and Market Forecasts
|出版日期||內容資訊||英文 208 Pages
|MediPoint:主動脈覆膜支架 - 歐盟市場分析與預測 MediPoint: Aortic Stent Grafts - EU Analysis and Market Forecasts|
|出版日期: 2014年10月31日||內容資訊: 英文 208 Pages||
Aortic stent grafts are most commonly used to reinforce a weak spot in an artery, which is known as an aneurysm. The stent grafts are designed to seal tightly with the patient's native artery above and below the aneurysm, and are used to treat abdominal aortic aneurysms as well as thoracic aortic aneurysms. Aortic aneurysms, as opposed to aneurysms found elsewhere in the body, are potentially very serious, as a burst aorta results in massive internal bleeding that can be fatal unless treated rapidly by an experienced emergency medical team. Since their introduction in patients in 1991, aortic stent graft devices have gained wide acceptance and availability, with their adoption fueled in great part by advances in stent-graft design and by a variety of devices for various anatomic features. Over time, these devices have gained traction for use in patients with ruptured aneurysms because they are minimally invasive and have shorter recovery times.
The EU market continues to be the second biggest market for aortic stent grafts at 23% of the global scene. Of this, Germany remains the leader as they are the pioneers of cardiovascular innovations and have a strong local manufacturing base. Similar to the US, the leading companies in the EU aortic stent grafts market are Medtronic, Cook Medical, and Gore Medical, with emerging players such as Endologix.